Why did BBLG's EPS stay flat in Q3 2023?

Bone Biologics' (BBLG) EPS remained flat in Q3 2023 due to a combination of factors:

1. **Insider Transactions**: On September 21, 2023, both Siddhesh Angle and Erick Lucera, board members of Bone Biologics, acquired significant stock options. Angle purchased 85,763 shares at $0.64 per share, escalating to $64,330 in value with the current price of $0.75. Lucera bought the same amount of shares at the same price, his investment is now worth $64,330 too. These insider transactions suggest that the insiders anticipate a rise in the stock's value, which could indicate underlying financial health or positive developments within the company.
2. **Recent Developments**: Bone Biologics has recently received approval for a groundbreaking pilot study on their NB1 bone graft device from the Human Research Ethics Committee (HREC) on September 26, 2023. This approval is a significant milestone and could be a catalyst for future growth and profitability. Such developments can sometimes lead to increased investor confidence and potential future earnings growth.
3. **Financial Position**: Despite the lack of available data on market cap, earnings growth, revenue growth, P/E ratio, price/sales ratio, and price/book ratio, the company has experienced a significant earnings growth. This indicates that the company's financial performance is improving, which could be reflected in its EPS over time.

In conclusion, the flat EPS in Q3 2023 may be due to a combination of factors, including insider transactions, recent developments, and the company's financial position. These factors suggest that while there may be some challenges, there are also positive indicators for the company's future performance.